Study guide
17.3 Oncologic, Immunotherapy & Hematologic Emergencies: Febrile Neutropenia, TLS, Hypercalcemia, irAEs, CAR-T, Hemophilia & TTP
BCEMP Board Certified Emergency Medicine Pharmacist Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction, Triage, and Resuscitation Fundamentals
1.1 BCEMP Exam Logistics, Content Outlines & Scoring 1.2 Emergency Triage Systems (ESI) & Pre-Hospital Care Coordination 1.3 Resuscitation Pharmacology, Pharmacokinetics & Vascular Access
2 Chapter 2: Cardiac Arrest and Dysrhythmias
2.1 Adult Cardiac Arrest & ACLS Pharmacotherapy Protocols 2.2 Acute Tachyarrhythmias: Narrow- and Wide-Complex Management 2.3 Symptomatic Bradycardia & Vasoactive Chronotropic Support 2.4 Post-Cardiac Arrest Care & Targeted Temperature Management (TTM)
3 Chapter 3: Shock and Hemodynamic Resuscitation
3.1 Sepsis & Septic Shock: Surviving Sepsis Campaign 2026 Resuscitation 3.2 Cardiogenic & Obstructive Shock, Mechanical Circulatory Support & LVADs 3.3 Hypovolemic & Hemorrhagic Shock Fluid Protocols
4 Chapter 4: Airway Management and Rapid Sequence Intubation (RSI)
4.1 Rapid Sequence Intubation (RSI) Process & Pretreatment Agents 4.2 RSI Induction Agents: Pharmacology, Selection & Dosing 4.3 Neuromuscular Blocking Agents & Post-Intubation Analgosedation
5 Chapter 5: Neurocritical Care and Neurologic Emergencies
5.1 Acute Ischemic Stroke: Thrombolysis & Blood Pressure Control 5.2 Intracranial Hemorrhage & Elevated ICP Pharmacotherapy 5.3 Status Epilepticus: Tiered Emergent Anticonvulsant Therapy 5.4 Traumatic Brain Injury & Spinal Cord Emergencies
6 Chapter 6: Acute Coronary Syndromes and Acute Heart Failure
6.1 Acute Coronary Syndromes: STEMI & NSTE-ACS Pharmacotherapy 6.2 Acute Decompensated Heart Failure & Cardiogenic Pulmonary Edema 6.3 Hypertensive Crises: Emergencies, Urgencies & Target Blood Pressure
7 Chapter 7: Pulmonary and Allergic Emergencies
7.1 Acute Pulmonary Embolism: Risk Stratification & Thrombolytic Therapy 7.2 Severe Asthma Exacerbation & COPD Acute Management 7.3 Anaphylaxis & Severe Allergic Reactions: Acute Epinephrine Protocols
8 Chapter 8: Clinical Toxicology: Approach to Poisoning and Common Overdoses
8.1 Approach to the Poisoned Patient: Poison Centers, Toxidromes, Decontamination & Enhanced Elimination 8.2 Acetaminophen Overdose & N-Acetylcysteine Dosing Strategies 8.3 Salicylate Toxicity & Toxic Alcohol Management (Fomepizole) 8.4 Opioid Toxicity & Sedative-Hypnotic/Alcohol Withdrawal Syndromes 8.5 Beta-Blocker & Calcium Channel Blocker Toxicity (HIET, Calcium, Glucagon)
9 Chapter 9: Toxicology: Specialized Poisonings and Antidotes
9.1 Digoxin, Tricyclic Antidepressants & Anticholinergic Toxicity 9.2 Cyanide, Carbon Monoxide & Organophosphate/Cholinergic Toxins 9.3 Snake and Spider Envenomations & Heavy Metal Chelation 9.4 Additional Antidotes: Methemoglobinemia, Isoniazid, Sulfonylureas, Valproate, Sympathomimetics & LAST
10 Chapter 10: Hemostasis, Anticoagulant Reversal, and Hematology
10.1 DOAC & Warfarin Reversal: Specific Reversal Agents & 4F-PCC 10.2 Heparin-Induced Thrombocytopenia (HIT) & Direct Thrombin Inhibitors 10.3 Sickle Cell Vaso-Occlusive Crises & Acute Chest Syndrome
11 Chapter 11: Endocrine, Electrolyte, and Metabolic Emergencies
11.1 Diabetic Ketoacidosis (DKA) & Hyperosmolar Hyperglycemic State (HHS) 11.2 Severe Electrolyte Emergencies: Hyperkalemia & Hyponatremia 11.3 Endocrine Crises: Thyroid Storm, Myxedema Coma & Acute Adrenal Crisis 11.4 Acute Kidney Injury, Dialyzability & Drug Dosing during RRT
12 Chapter 12: Infectious Diseases and Antimicrobial Stewardship
12.1 Severe Community & Hospital-Acquired Infections in the ED 12.2 Skin & Soft Tissue, STI, and Vector-Borne Emergencies 12.3 ED Antimicrobial Stewardship & Rapid Microbiologic Diagnostics
13 Chapter 13: Special Populations: Pediatrics, Trauma, and Obstetrics
13.1 Pediatric Resuscitation, Status Epilepticus & PALS Pharmacotherapy 13.2 Trauma Pharmacotherapy: Massive Transfusion, TXA, Open Fractures, Tetanus & Burns 13.3 Obstetric & Gynecologic Emergencies: Preeclampsia, Eclampsia & PPH
14 Chapter 14: Medication Safety, ED Operations, and Disaster Preparedness
14.1 ED High-Alert Medications, Error Reporting & Technology Safeguards 14.2 ED Workflow, Transitions of Care & Boarding Patient Management 14.3 Mass Casualty Incidents, CBRNE Countermeasures & Strategic Stockpiles
15 Chapter 15: Biostatistics, Study Design, and Literature Evaluation
15.1 Biostatistics & Hypothesis Testing: Power, Errors & Interpretations 15.2 Clinical Study Designs & Measures of Effect 15.3 Literature Evaluation, Clinical Guidelines & Research Conduct in the ED
16 Chapter 16: Medical Devices, Ventilation, and Medication Delivery
16.1 Mechanical Ventilation, Noninvasive Ventilation & High-Flow Oxygen: What the Pharmacist Must Know 16.2 Vascular Access, Enteral Tubes, Drains & Extravasation Management 16.3 Infusion Pumps, Patient-Owned Devices & Medication Delivery Device Counseling
17 Chapter 17: Organ-System Emergencies: GI, GU, Oncology, Neurology, ENT, Pain, and Psychiatry
17.1 Gastrointestinal & Hepatic Emergencies: GI Bleeding, Cirrhosis Complications, Pancreatitis & Vomiting 17.2 Genitourinary Emergencies: UTI & Pyelonephritis, Renal Colic, Urinary Retention, Priapism & Scrotal Infections 17.3 Oncologic, Immunotherapy & Hematologic Emergencies: Febrile Neutropenia, TLS, Hypercalcemia, irAEs, CAR-T, Hemophilia & TTP 17.4 Headache & Neuromuscular Emergencies: Migraine, Cluster, Myasthenic Crisis, Guillain-Barré & Bell's Palsy 17.5 Ophthalmologic, ENT & Dental Emergencies: Eye Injuries, Angle Closure, Angioedema, Epistaxis, Ear & Throat Infections and Dental Pain 17.6 Acute Pain Management & Procedural Sedation and Analgesia in the ED 17.7 Psychiatric Emergencies: Severe Agitation, Serotonin Syndrome, NMS, Lithium Toxicity & Psychotropic Overdose
18 Chapter 18: Special Populations, Medication Access, and Professional Practice
18.1 Pharmacogenomics, Adverse Drug Events & High-Risk Drug Interactions in Emergency Care 18.2 Special Populations: Older Adults, Extremes of Weight, Pregnancy & Lactation, and Immunocompromised Patients 18.3 Social Determinants of Health, Health Literacy & Medication Access at ED Discharge 18.4 Healthcare Regulations & Standards: FDA, REMS, Bar Coding, DEA, CMS, EMTALA, The Joint Commission, NIOSH & USP 18.5 Formulary & Inventory Management, Drug Shortages, Antidote Stocking & Clinical Decision Support 18.6 Quality Improvement, Practice Standards & Interprofessional Collaboration (Protocols, Teamwork & Debriefing)
17.3 Oncologic, Immunotherapy & Hematologic Emergencies: Febrile Neutropenia, TLS, Hypercalcemia, irAEs, CAR-T, Hemophilia & TTP
Key Takeaways Explain This Topic AI
Febrile neutropenia (ANC below 500 cells/mm3 with a temperature of 38.3 °C, or 38.0 °C sustained for 1 hour) needs an antipseudomonal beta-lactam such as cefepime 2 g IV within 60 minutes.
Rasburicase rapidly lowers uric acid in tumor lysis syndrome, but it is contraindicated in G6PD deficiency because it causes hemolysis and methemoglobinemia.
The 2023 Endocrine Society guideline suggests denosumab over IV bisphosphonates for hypercalcemia of malignancy, adding calcitonin for 48 to 72 hours when calcium exceeds 14 mg/dL.
Tocilizumab 8 mg/kg (maximum 800 mg) treats cytokine release syndrome after CAR-T therapy, while isolated neurotoxicity (ICANS) is treated with dexamethasone.
In hemophilia A, each unit/kg of factor VIII raises activity about 2%, so a 70-kg patient needs about 3,500 units to reach 100%; give factor before imaging for head trauma.
Last updated: October 2026
17.3 Oncologic, Immunotherapy & Hematologic Emergencies: Febrile Neutropenia, TLS, Hypercalcemia, irAEs, CAR-T, Hemophilia & TTP
Note
Exam scope: 2025 outline subtopic 2B4 (Immunology, Oncology and Hematology). Anticoagulant reversal (Section 10.1), heparin-induced thrombocytopenia (Section 10.2) and sickle cell disease (Section 10.3) are covered elsewhere. Chemotherapy extravasation is covered in Section 16.2.
Febrile Neutropenia
Definitions (IDSA):
Fever: a single oral temperature of 38.3 °C or higher , or 38.0 °C or higher sustained for 1 hour .
Neutropenia: an ANC below 500 cells/mm3 , or expected to fall below 500 within 48 hours.
Neutropenic patients may show few signs of infection, so treat fever as an emergency. Draw blood cultures (from each catheter lumen and a peripheral site), then give an antipseudomonal beta-lactam within 60 minutes :
- Agent Typical adult dose
- Cefepime 2 g IV every 8 hours
- Piperacillin-tazobactam 4.5 g IV every 6 hours
- Meropenem 1 g IV every 8 hours (preferred with ESBL risk)
Add vancomycin only for specific indications: hemodynamic instability, suspected catheter infection, skin or soft tissue infection, pneumonia, known MRSA colonization, or Gram-positive cocci in blood cultures before identification. Routine empiric vancomycin does not improve outcomes.
Low-risk outpatients (MASCC score of 21 or higher, or a low CISNE score, with reliable follow-up) can receive oral ciprofloxacin plus amoxicillin-clavulanate after an observation period (ASCO/IDSA 2018). Clindamycin can replace amoxicillin-clavulanate for penicillin allergy.
Tumor Lysis Syndrome (TLS)
TLS follows rapid cell death, usually within days of starting therapy for bulky, fast-growing cancers such as Burkitt lymphoma, acute leukemias and high-grade lymphomas. It can also occur on its own.
Cairo-Bishop laboratory criteria (two or more within 3 days before to 7 days after therapy):
- Uric acid of 8 mg/dL or more
- Potassium of 6 mEq/L or more
- Phosphate of 4.5 mg/dL or more (adults)
- Calcium of 7 mg/dL or less
Clinical TLS means laboratory TLS plus AKI, dysrhythmia, seizure or sudden death.
Intervention Details
Hydration About 2 to 3 L/m2 a day, aiming for urine output of at least 80 to 100 mL/m2/h; avoid potassium in fluids
Allopurinol Blocks new uric acid formation but does not remove existing uric acid; adjust for kidney function; interacts with azathioprine and mercaptopurine
Rasburicase Converts uric acid to allantoin within hours. Labeled dose is 0.2 mg/kg daily for up to 5 days; a single fixed dose (3 to 6 mg) is common practice with repeat doses as needed
Urine alkalinization Not recommended : it promotes calcium phosphate and xanthine precipitation
Hyperkalemia, hyperphosphatemia Standard potassium treatment (Section 11.2) and phosphate binders; early nephrology involvement for dialysis
Hypocalcemia Treat only symptomatic hypocalcemia; giving calcium when phosphate is high causes calcium phosphate deposition
Warning
Rasburicase boxed warnings: anaphylaxis, hemolysis and methemoglobinemia in G6PD deficiency (screen high-risk patients first), and falsely low uric acid levels. Rasburicase keeps working in the blood tube, so samples must be collected in prechilled heparin tubes, kept on ice and assayed within 4 hours.
Hypercalcemia of Malignancy
The 2023 Endocrine Society guideline :
Recommends an IV bisphosphonate or denosumab for all patients with hypercalcemia of malignancy.
Suggests denosumab over an IV bisphosphonate.
For severe hypercalcemia (calcium above 14 mg/dL), suggests adding calcitonin , limited to 48 to 72 hours because of tachyphylaxis.
For refractory or recurrent hypercalcemia despite bisphosphonates, suggests adding denosumab.
For tumors that produce calcitriol (lymphomas), suggests glucocorticoids.
Agent Dose Onset Notes
Normal saline Bolus, then about 200 to 300 mL/h to restore volume Hours Give a loop diuretic only after volume repletion, or for fluid overload
- Calcitonin 4 units/kg SC or IM every 12 hours 4 to 6 hours Short-lived because of tachyphylaxis
- Zoledronic acid 4 mg IV over at least 15 minutes 2 to 4 days Nephrotoxic; check kidney function
- Denosumab 120 mg SC Days Not cleared by the kidneys; high risk of hypocalcemia in advanced CKD
- Other Structural Oncologic Emergencies
Malignant spinal cord compression: back pain with neurologic deficits in a patient with cancer. Give dexamethasone (commonly 10 mg IV, then 4 mg every 6 hours) and obtain an MRI of the whole spine urgently, followed by radiation or surgery. Very high doses (around 96 mg) add toxicity without clear benefit.
Superior vena cava syndrome: facial and arm swelling with distended neck veins. Give steroids only for steroid-responsive tumors such as lymphoma or thymoma, ideally after tissue diagnosis. Stenting gives rapid relief, and anticoagulation is added if there is thrombus.
Hyperleukocytosis with leukostasis: avoid red cell transfusion where possible because it raises blood viscosity. Treatment includes cytoreduction (hydroxyurea or induction chemotherapy), TLS prophylaxis and leukapheresis in selected patients.
Immune Checkpoint Inhibitor Toxicities
PD-1, PD-L1 and CTLA-4 inhibitors can cause immune-related adverse events (irAEs) in any organ, sometimes months after the last dose. Ask every patient with cancer about immunotherapy.
General approach (ASCO 2021):
- Grade Action
- Grade 1 Usually continue the checkpoint inhibitor with close monitoring
- Grade 2 Hold the inhibitor; give prednisone 0.5 to 1 mg/kg/day
- Grade 3 Hold; give methylprednisolone or prednisone 1 to 2 mg/kg/day
- Grade 4 Permanently discontinue (for most organs); give high-dose steroids
Steroids are tapered over at least 4 to 6 weeks.
Organ-specific points:
Colitis not improving within 48 to 72 hours of steroids: add infliximab or vedolizumab.
Hepatitis that does not respond to steroids: use mycophenolate. Avoid infliximab because of its own liver toxicity.
Myocarditis: high mortality; give methylprednisolone 500 to 1,000 mg daily and admit to a monitored bed.
Endocrinopathies (hypophysitis, adrenal insufficiency, thyroiditis, type 1 diabetes presenting as DKA): replace hormones. Adrenal crisis needs stress-dose hydrocortisone (Section 11.3). These conditions are usually permanent.
CAR-T Cell Therapy: CRS and ICANS
Autologous CD19- and BCMA-directed CAR-T therapies cause cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) . In June 2025, FDA removed the REMS programs for these products and shortened the recommended period for staying near the treatment center and avoiding driving to 2 weeks. Toxicity can still present to any ED.
Syndrome Features Treatment
CRS Fever, then hypotension and hypoxia; graded by the need for vasopressors and oxygen (ASTCT) Tocilizumab 8 mg/kg IV over 1 hour (maximum 800 mg) , repeated at least 8 hours apart if needed (up to 3 doses in 24 hours, 4 in total); add dexamethasone for higher grades or no response
ICANS Word-finding difficulty, impaired handwriting, confusion, seizures, cerebral edema; graded with the ICE score Dexamethasone 10 mg IV every 6 hours for grade 2 or higher. Tocilizumab does not treat isolated ICANS and may worsen it. Levetiracetam is commonly used to prevent seizures
Treat fever in these patients as neutropenic fever as well, because infection and CRS often overlap.
- Bleeding Disorders and Immune Platelet Disorders
- Hemophilia
Give factor replacement first, then image. A patient with hemophilia and a head injury or suspected serious bleed should receive factor before the CT scan (World Federation of Hemophilia). Patients often carry their own factor and a letter describing their treatment plan.
- Deficiency Expected rise Dose for a target level
- Factor VIII (hemophilia A) About 2% per unit/kg Weight (kg) × desired rise (%) × 0.5
- Factor IX (hemophilia B) About 1% per unit/kg (standard products) Weight (kg) × desired rise (%) × 1
Worked example: a 70-kg man with severe hemophilia A (under 1%) and an intracranial hemorrhage needs a target of about 100%. 70 × 100 × 0.5 = 3,500 units of factor VIII.
Patients with inhibitors need bypassing agents: recombinant factor VIIa or activated prothrombin complex concentrate (aPCC). Many patients now receive emicizumab prophylaxis, which distorts aPTT-based tests. aPCC given with emicizumab (more than 100 units/kg/day for more than 24 hours) has caused thrombotic microangiopathy and thrombosis, a boxed warning. Recombinant factor VIIa is preferred for breakthrough bleeding in these patients.
Thrombotic Thrombocytopenic Purpura (TTP)
The classic picture is microangiopathic hemolytic anemia with schistocytes, severe thrombocytopenia and organ injury from severe ADAMTS13 deficiency. It is a medical emergency:
- Therapeutic plasma exchange , with plasma infusion as a bridge
- Corticosteroids and rituximab
- Caplacizumab 11 mg IV before the first exchange, then 11 mg SC daily
- Avoid platelet transfusion unless bleeding is life-threatening, because it can worsen thrombosis
- Immune Thrombocytopenia (ITP)
ASH (2019) recommends treatment when platelets are below 30,000/mm3 or there is bleeding:
- Prednisone 1 mg/kg (for no more than 6 weeks), or dexamethasone 40 mg daily for 4 days
- IVIG 1 g/kg when a rapid rise is needed
Life-threatening bleeding: platelet transfusion with IVIG and high-dose IV methylprednisolone, with a thrombopoietin receptor agonist considered